Clinical Trials Browser

Phase 2 × Has announcements × Lymphoma, Large B-Cell, Diffuse × Clear all

NCT02227251 2025-10-01

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Recruiting

244 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02445248 2024-04-18

JULIET

Phase 2 Completed

115 enrolled 22 charts 1 FDA

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03483103 2023-12-20

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Phase 2 Completed

74 enrolled 43 charts 1 FDA

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 2 FDA

Lymphoma, Large B-Cell, Diffuse